Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma - Trial NCT05798455
Access comprehensive clinical trial information for NCT05798455 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Tabriz University of Medical Sciences and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tabriz University of Medical Sciences
Timeline & Enrollment
Phase 1/2
May 22, 2023
May 22, 2026
Primary Outcome
Maximum tolerated dose (MTD) and/or recommended dose,Objective response rate
Summary
This study investigates the safety and efficacy of sodium pentaborate pentahydrate in
 patients with advanced renal cell carcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05798455
Non-Device Trial